Search results
Regeneron is a biotech company that develops new medicines for serious diseases using novel technologies. Learn about its history, research areas, clinical trials, responsibility goals, and career opportunities.
- Career Opportunities
Working at Regeneron We are a team of original thinkers who...
- Approved Medicines
Regeneron (NASDAQ: REGN) is a leading biotechnology company...
- Locations & Contact
An important note about privacy: Regeneron is committed to...
- Investigational Pipeline
UPDATE: Due to the high circulation of the SARS-CoV-2...
- Leadership
Leonard (Len) Brooks joined Regeneron in 2013 and serves as...
- About
Reinventing Drug Discovery. For 35 years, our mission has...
- Investor Relations
We are a leading science and technology company that...
- Medical Professionals
Regeneron’s Compassionate Use Policy gives certain patients...
- Collaborations
In an example of a commercial-stage agreement, Regeneron...
- Career Opportunities
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase ...
Regeneron is a biotech company that invents, develops and commercializes life-transforming medicines for serious diseases. It uses proprietary technologies, genetics research and ESG initiatives to push the bounds of science and improve patient lives.
Regeneron is a biotechnology company that develops and produces medicines for serious diseases across multiple therapeutic areas. Learn about its FDA-approved products, investigational pipeline, clinical trials and industrial operations.
Mar 23, 2021 · Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive Phase 3 outcomes trial in high-risk non-hospitalized COVID-19 patients ("outpatients") met its primary endpoint, showing the ...
Regeneron developed a combination of monoclonal antibodies to treat COVID-19, which received emergency use authorization in 2020. The company also has ongoing research on new and existing variants, and collaborates with BARDA and Roche.
People also ask
Where is Regeneron Pharmaceuticals headquartered?
Is Regeneron a free drug?
What does Regeneron do?
Who invented Regeneron?
